TrialTargeted oncology2016
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
John D Hainsworth et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
40 papers cite it
this paperpooled ittrialcites it